Advertisement
Home Tags Survival

Tag: Survival

Statin Use Improves Outcomes in Chronic, Small Lymphocytic Leukemia

0

Improvements seen in overall survival, progression-free survival, and cancer-specific survival

Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC

0

Predictors of longer postdiscontinuation progression-free survival include complete/partial response, longer treatment duration

Disparities Evident in Treatment, Survival for Patients With Pancreatic Cancer

0

Lower odds of receiving key components of quality care seen for those with high overall social vulnerability index

Healthy Nutrition, Activity May Reduce Mortality Risk for Cancer Survivors

0

Adherence to American Cancer Society guidelines linked to lower mortality in nonsmoking survivors of obesity-related cancer

Study Looks at Recovery Potential in Comatose Patients Who Died After Halting Life-Sustaining Therapy

0

Most patients who died after withdrawal of life-sustaining therapy were considered to have recovery potential of at least 1 percent

Molecular Residual Disease Analysis May Predict Disease Recurrence After Lung Cancer Resection

0

Molecular residual disease precedes DFS events in patients receiving osimertinib, placebo; most events occur after osimertinib discontinuation or completion

Physical Activity Linked to Attenuation of Colon Cancer Survival Disparity

0

Physical activity attenuates survival disparity between patients with stage III colon cancer and matched population controls

Acalabrutinib-Venetoclax Prolongs Survival in Previously Untreated Leukemia

0

Progression-free survival significantly lower with fixed-duration acalabrutinib-venetoclax with or without obinutuzumab

Black Patients With Cancer Still Have Higher Mortality Rates Than Whites

0

Relative decline seen in cancer mortality among Blacks, but they still have higher mortality rates than Whites

Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC

0

Significant and clinically relevant improvement seen in objective response rate with encorafenib + cetuximab plus mFOLFOX6